COP vs RNAC · P/E 19, rev $58.94B vs P/E 2.1, rev $38.9M
ConocoPhillips (COP) versus Cartesian Therapeutics Inc. (RNAC) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported RNAC revenue for 2024-12-31 was $38.9M. Net income was -$77.4M. Revenue was up 49.6% from 2023-12-31 to 2024-12-31. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
COP currently screens at market cap $135.49B and trailing P/E 18.8. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Not investment advice. Open the COP and RNAC stock pages for the full models.
Not investment advice.